Pharm4.0 PIC/S 智慧製藥未來的探討

Abstract

中文摘要 本研究認為，台灣小分子既有設備(Brownfield)藥廠推動智慧製藥，不宜追求一次到位的智慧工廠。本研究利用系統思考進行分析，將智慧製藥視為設備條件、資料治理、法規驗證、人才能力、組織文化與投資決策相互影響的動態過程。因此，較可行的方式應採取「分階段、低風險、循序擴大」的導入路徑。 第一階段，藥廠應先進行全廠設備盤點、流程合理化與資料治理，確認既有設備狀態、資料來源、通訊介面、人工紀錄流程與法規驗證需求，降低後續系統導入的不確定性。 第二階段，應優先導入低風險且效益明確的數位化項目，例如 ERP 資料透明化、QMS/EDMS、CDS、環境監控、QC/IPQC 實驗室自動化、稱量、包裝、自動倉儲與 LIMS 初期導入，提升 Data Integrity。此階段若能產生明確效益與高層支持，形成後續再投資的正向增強環路。 第三階段，藥廠可透過 Gateway、OPC UA或中介層逐步整合既有設備資料，避免停機風險，並建立 IT/OT 整合能力。此階段需注意老舊設備、CSV 驗證負擔與 ROI 不確定所形成的調節環路，避免導入速度過快而增加組織阻力。 第四階段，待數據完整性(Data Integrity)、CSV、跨部門團隊與現場使用文化成熟後，再推動 MES/eBR，整合生產工單、批次紀錄、製程參數、偏差管理與品質審查，提升製造現場的即時監控與管理效率。 第五階段，藥廠可選擇低風險製程或關鍵品質屬性作為 製程分析技術(PAT)試點，逐步建立 CPP 與 CQA 關聯，再發展 AI 輔助分析、RTRT 與 Explainable AI。此階段應重視資料品質、模型驗證、可解釋性與持續監控，避免模型治理成本形成新的導入阻力。 整體而言，台灣小分子藥廠推動智慧製藥，應先建立低風險成功案例，再逐步擴大導入範圍。從系統思考角度來看，製藥4.0 (Pharma 4.0) 的成功關鍵在於強化「數位投資—Data Integrity 提升—審查效率提高—管理信心增加—再投資」的增強環路，同時降低「老舊設備—IT/OT 成本—CSV 負擔—ROI 不確定—導入速度下降」的調節環路。Pharma 4.0 應被視為長期能力建置，而非單次系統採購，其核心目的在於提升資料透明度、製程理解、法規合規能力、批次審查效率與國際 CDMO 客戶信任，建立台灣藥廠差異化競爭優勢。

Abstract This study argues that Taiwanese small-molecule brownfield drug manufacturers should not aim for a one shot smart factory. Using systems thinking, smart pharma is viewed as a dynamic interplay of equipment, data governance, regulatory validation, skills, culture, and investment decisions. A pragmatic approach is “phased, low risk, and incremental.” Phase 1: Inventory equipment, streamline processes, and establish data governance—identify equipment condition, data sources, interfaces, manual records, and validation needs to reduce uncertainty for later system integration. Phase 2: Deploy low risk, high value digital projects first (ERP transparency, QMS/EDMS, CDS, environmental monitoring, QC/IPQC lab automation, weighing, packaging, automated warehousing, initial LIMS) to improve Data Integrity and generate visible benefits that build leadership support. Phase 3: Gradually integrate equipment data via Gateways, OPC UA or middleware to avoid downtime and develop IT/OT integration capabilities. Manage risks from legacy assets, CSV burden, and uncertain ROI to prevent organizational resistance. Phase 4: After Data Integrity, CSV practices, cross functional teams, and shop floor adoption mature, implement MES/eBR to unify work orders, batch records, process parameters, deviation handling, and quality review for better real time control. Phase 5: Pilot PAT on low risk processes or critical quality attributes to link CPPs and CQAs, then expand to AI assisted analysis, RTRT, and explainable AI—while ensuring data quality, model validation, interpretability, and monitoring to avoid new governance costs that hinder adoption. Conclusion: Build low risk successes and scale gradually. From systems thinking, Pharma 4.0 success hinges on reinforcing the loop “digital investment → improved Data Integrity → faster reviews → greater management confidence → reinvestment” while reducing the balancing loop driven by legacy equipment, IT/OT costs, CSV burden, and uncertain ROI. Treat Pharma 4.0 as long term capability building—not a single purchase—to improve data transparency, process understanding, regulatory compliance, batch review efficiency, and CDMO credibility, creating a differentiated advantage for Taiwanese drugmakers.